Plasma atrial natriuretic peptide in DOCA-NaCl-treated rats

Acta Physiol Scand. 1987 Feb;129(2):151-5. doi: 10.1111/j.1748-1716.1987.tb08053.x.

Abstract

In order to assess the possible role of atrial natriuretic peptide (ANP) in the development of deoxycorticosterone (DOCA)-NaCl-induced hypertension, plasma immunoreactive ANP concentration was compared with sodium balance and blood pressure in NaCl- or DOCA-NaCl-treated rats. Both NaCl-and DOCA-NaCl-loading increased plasma ANP levels (to 86 +/- 8.1 and 105 +/- 12 pg ml-1 respectively; 47 +/- 6.7-60 +/- 4.6 pg ml-1 in controls), which were correlated to sodium intake and excretion. In DOCA-NaCl-treated rats, the highest ANP levels (105 +/- 12 pg ml-1) were found 4 weeks after the beginning of DOCA-NaCl treatments. Along with the development of DOCA-NaCl hypertension in 1-kidney-DOCA-NaCl-treated rats, however, plasma ANP concentration did not rise further. We conclude that secretion of ANP into the circulation is increased during DOCA-NaCl treatment. Elevated blood pressure does not stimulate ANP release in DOCA-NaCl-treated rats further.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atrial Natriuretic Factor / blood*
  • Desoxycorticosterone / pharmacology*
  • Female
  • Hypertension / blood
  • Hypertension / chemically induced
  • Rats
  • Rats, Inbred Strains
  • Renin / blood
  • Sodium / urine
  • Sodium Chloride / pharmacology*
  • Water-Electrolyte Balance / drug effects

Substances

  • Desoxycorticosterone
  • Sodium Chloride
  • Atrial Natriuretic Factor
  • Sodium
  • Renin